Silence Therapeutics PLC (SLN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.23B
Last updated: Nov 17, 2026 at 11:05 AM ET
Silence Therapeutics PLC (SLN) Competitors
The companies most similar to Silence Therapeutics are Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT) and Sellas Life Sciences Group (SLS). By market cap, Silence Therapeutics ranks 11th of the 13 companies on this page; Stoke Therapeutics (STOK) is the largest at $1.75B.
Peer Comparison
SLN's revenue growth of 197.2% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Silence Therapeutics (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Sellas Life Sciences Group Inc (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.55B | N/A | 59.3x | 0.0% | N/A | 0.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Stoke Therapeutics Inc (STOK) | $1.75B | N/A | 64.5x | 0.0% | N/A | 5.9% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Peer median | $1.49B | 10.3x | 2.6x | 0.0% | -26.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Silence Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Sellas Life Sciences Group Inc (SLS) | SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications... | SLS competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Rapport Therapeutics, Inc. Common Stock (RAPP) | Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases... | RAPP competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Stoke Therapeutics Inc (STOK) | Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious... | STOK competitors |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
Frequently Asked Questions About SLN
Who are Silence Therapeutics' main competitors?
The companies most similar to Silence Therapeutics include Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT), Sellas Life Sciences Group (SLS), Rigel Pharmaceuticals (RIGL) and Intellia Therapeutics (NTLA), listed from the closest match.
Who is Silence Therapeutics' biggest competitor?
Stoke Therapeutics (STOK) is the largest of the similar companies at $1.75B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.
How does SLN stock compare with its competitors?
SLN's P/S is 882.5x against a peer median of 2.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Silence Therapeutics' competitors pays a higher dividend?
Silence Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Silence Therapeutics bigger than its competitors?
No. Silence Therapeutics is 11th by market cap among the 13 companies on this page; the largest is Stoke Therapeutics (STOK) at $1.75B.
SLN pages: Overview, Financials, Competitors